cancer, all types
DISEASE INTERVENTION COMPARISON RESULTS
Am J Med. 2012 Jun;125(6):560-7 Systematic Review
IN cancer, all types The Use of
aspirin, 75 mg daily or more, for at least 2.8 years
As Prevention, Primary
Is better Than
placebo
To reduce cancer deaths (2% aspirin VS 2.6% placebo) and noncardiovascular mortality (2.3% VS 2.6%)
Lancet. 2011 Jan 1;377(9759):31-41. Epub 2010 Dec 6 Meta-Analysis
IN cancer, all types, gastrointestinal cancers The Use of
aspirin, 75 mg daily or more, for more than 5 years
As Prevention, Primary
Is better Than
placebo
To reduce death due to all cancers (0.79) when treatment maintained for more than 5 years, specially for gastrointestinal cancers (OR 0.46) but also for brain, lung and prostate cancers.
J Gerontol A Biol Sci Med Sci. 2016 Dec;71(12):1653-1660 Cohorts
IN cancer, all types, older patients The Use of
classificating patients in 4 classes: four classes: relatively healthy (LC1), malnourished (LC2), cognitive and mood impaired (LC3), and globally impaired (LC4)
As Prognostic Item
Is useful Than
no classification
To predict overall 1-year mortality and 6-month unscheduled admissions